Premium
Association between in vivo iododeoxyuridine labeling, MIB‐1 expression, malignancy grade and clinical stage in human prostate cancer
Author(s) -
BORRE MICHAEL,
HØYER MORTEN,
SØRENSEN FLEMMING BRANDT,
NERSTRØM BENNI,
OVERGAARD JENS
Publication year - 1998
Publication title -
apmis
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.909
H-Index - 88
eISSN - 1600-0463
pISSN - 0903-4641
DOI - 10.1111/j.1699-0463.1998.tb01362.x
Subject(s) - in vivo , malignancy , immunohistochemistry , prostate , stage (stratigraphy) , prostate cancer , medicine , cancer research , pathology , cancer , cell growth , clinical significance , oncology , biology , paleontology , genetics , microbiology and biotechnology
Large variability in the biological behavior of prostate cancer makes prognostic markers important. The extent of tumor cell proliferation has been suggested as an important predictor of clinical outcome. Fifty‐five patients suspected of having or with previously diagnosed prostate cancer were labeled in vivo with IdUrd (a thymidine analogue incorporated into DNA in S‐phase cells) by intravenous infusion before transurethral resection. IdUrd‐labeled cells and MIB‐1‐positive cells were detected by immunohistochemistry. We found statistically significant associations between the tumor cell proliferation rates measured by in vivo IdUrd labeling and MIB‐1 expression in formalin‐fixed paraffin‐embedded tumors. Good correlations were also found between S‐phase fraction, MIB‐1 expression, clinical stage and malignancy grade. These results make larger retrospective studies on archival tissue meaningful.